STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study
Stat News • 2/12/2026
Summary
BridgeBio Pharma's experimental drug for the most common cause of dwarfism has shown success in a pivotal clinical trial by accelerating children's growth.
Advertisement
Lindy Score Breakdown (V4.2)
50d
Age
1
Sources
from cluster
1211
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1211/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1211/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 50 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News • 1 day ago
STAT+: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures
Stat News • 1 day ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • Today
STAT+: Biotech investors’ plea to Trump, and a busy M&A week
Stat News • Today
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • 1 day ago
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
Stat News • 1 day ago
STAT+: White House proposes 12% cut to federal health agencies in 2027 budget request
Stat News • Today
STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along
Stat News • Today
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago